In recent years, other serum biomarkers have been used to provide insights into MS risk and progression, such as glial fibrillary acidic protein (GFAP), whose levels increase in people with inflammatory neuronal damage due to possible new flare-ups and decrease when treatments keep the disease stable [7]. The gene discussed is GFAP; the disease is myeloid sarcoma.